DEVELOPMENT AND VALIDATION OF A METHOD FOR DETECTING THE BRAF V600E SOMATIC MUTATION BY THE ALLELE-SPECIFIC LAMP METHOD
Main Article Content
Authors
M.L. Filipenko
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
E.A. Khrapov
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
D.V. Shamovskaya
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
M.A. Smertina
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
I.P. Obrabin
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
U.A. Boyarskikh
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
Abstract
Detection of the somatic BRAF V600E mutation is a mandatory component of molecular stratification in melanoma, as its presence determines eligibility for BRAF and MEK inhibitor therapy [1–4]. Although qPCR- and NGS-based platforms remain the most widely used approaches for BRAF V600 mutation testing, interest in simpler, faster, and more cost-effective isothermal amplification formats persists [7, 22].
To develop and validate an allele-specific loop-mediated isothermal amplification (LAMP) assay for detection of the somatic BRAF V600E mutation in DNA extracted from tumour tissue.
An allele-specific LAMP format was employed. Analytical performance was characterised using linearised plasmid controls pV600WT and pV600E and their mixtures. Diagnostic validation was performed on 67 DNA samples extracted from FFPE melanoma blocks. The cobas 4800 BRAF V600 Mutation Test was used as the reference method.
The analytical limit of detection for mutant allele fraction was 1%, and the LoD₅₉ for mutant allele copy number was 200 copies per reaction. In the clinical sample set, sensitivity of LAMP-V600E relative to AS-qPCR was 93.5% (29/31), specificity 100% (36/36), positive predictive value 100%, negative predictive value 94.7%, overall accuracy 97.0%, and Cohen’s kappa coefficient 0.940. The two false-negative results were most likely attributable to FFPE-DNA degradation and the greater sensitivity of LAMP to template integrity over the comparatively longer amplification target [23, 24].
The developed allele-specific LAMP assay for BRAF V600E detection demonstrates high specificity, acceptable clinical sensitivity, and strong concordance with the reference AS-qPCR platform. The assay may be considered a rapid and technically accessible option for tissue-based BRAF testing; however, the quality and quantity of FFPE-derived DNA must be taken into account for reliable performance.
Keywords
BRAF V600E, LAMP, melanoma, FFPE, molecular diagnostics, targeted therapy
Article Details
References
Amaral T., Ottaviano M., Arance A., et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // Annals of Oncology. – 2025 Jan; – Vol. 36. – No. 1. – P.10–30 // doi: 10.1016/j.annonc.2024.11.006.
Swetter S.M., Johnson D.B., Albertini M.R., et al. NCCN Guidelines Insights: Melanoma: Cutaneous, Version 2.2024 // Journal of the National Comprehensive Cancer Network. – 2024 May; – Vol. 22. – No. 5. – P.290–298 // doi: 10.6004/jnccn.2024.0036.
Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation // New England Journal of Medicine. – 2011 Jun; – Vol. 364. – No. 26. – P.2507–2516 // doi: 10.1056/NEJMoa1103782.
Robert C., Grob J.J., Stroyakovskiy D., et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma // New England Journal of Medicine. – 2019 Aug; – Vol. 381. – No. 7. – P.626–636 // doi: 10.1056/NEJMoa1904059.
Dummer R., Ascierto P.A., Gogas H.J., et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma: a multicentre, open-label, randomised phase 3 study // Lancet Oncology. – 2018 May; – Vol. 19. – No. 5. – P.603–615 // doi: 10.1016/S1470-2045(18)30142-6.
Notomi T., Okayama H., Masubuchi H., et al. Loop-mediated isothermal amplification of DNA // Nucleic Acids Research. – 2000 Jun; – Vol. 28. – No. 12. – P.e63 // doi: 10.1093/nar/28.12.e63.
Notomi T., Mori Y., Tomita N., Kanda H. Loop-mediated isothermal amplification (LAMP): principle, features, and future prospects // Journal of Microbiology. – 2015 Jan; – Vol. 53. – No. 1. – P.1–5 // doi: 10.1007/s12275-015-4656-9.
Nagamine K., Hase T., Notomi T. Accelerated reaction by loop-mediated isothermal amplification using loop primers // Molecular and Cellular Probes. – 2002 Jun; – Vol. 16. – No. 3. – P.223–229 // doi: 10.1006/mcpr.2002.0415.
Tomita N., Mori Y., Kanda H., Notomi T. Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products // Nature Protocols. – 2008 May; – Vol. 3. – No. 5. – P.877–882 // doi: 10.1038/nprot.2008.57.
Oscorbin I.P., Belousova E.A., Boyarskikh U.A., Zakabunin A.I., Khrapov E.A., Filipenko M.L. Derivatives of Bst-like Gss-polymerase with improved processivity and inhibitor tolerance // Nucleic Acids Research. – 2017 Sep; – Vol. 45. – No. 16. – P.9595–9610 // doi: 10.1093/nar/gkx645.
Shirshikov F.V., Bespyatykh J.A. Loop-mediated isothermal amplification: from theory to practice // Russian Journal of Bioorganic Chemistry. – 2022 Nov; – Vol. 48. – No. 6. – P.1159–1174 // doi: 10.1134/S106816202206022X.
Varona M., Anderson J.L. Advances in mutation detection using loop-mediated isothermal amplification // ACS Omega. – 2021 Feb; – Vol. 6. – No. 5. – P.3463–3469 // doi: 10.1021/acsomega.0c06093.
Papadakis G., Pantazis A.K., Fikas N., et al. Portable real-time colorimetric LAMP-device for rapid quantitative detection of nucleic acids in crude samples // Scientific Reports. – 2022 Mar; – Vol. 12. – No. 1. – P.3775 // doi: 10.1038/s41598-022-06632-7.
Varona M., Eitzmann D.R., Pagariya D., Anand R.K., Anderson J.L. Solid-phase microextraction enables isolation of BRAF V600E circulating tumour DNA from human plasma for detection with a molecular beacon loop-mediated isothermal amplification assay // Analytical Chemistry. – 2020 Feb; – Vol. 92. – No. 4. – P.3346–3353 // doi: 10.1021/acs.analchem.9b05323.
Etemadzadeh A., Salehipour P., Movahedi Motlagh F., et al. An optimized CRISPR/Cas12a assay to facilitate the BRAF V600E mutation detection // Journal of Clinical Laboratory Analysis. – 2024 Nov; – Vol. 38. – No. 21. – P.e25101 // doi: 10.1002/jcla.25101.
Dekaliuk M., Qiu X., Troalen F., Busson P., Hildebrandt N. Discrimination of the V600E mutation in BRAF by rolling circle amplification and Förster resonance energy transfer // ACS Sensors. – 2019 Oct; – Vol. 4. – No. 10. – P.2786–2793 // doi: 10.1021/acssensors.9b01420.
Moráňová L., Strmisková J., Ondrašková K., et al. Electrochemical detection of BRAF V600E mutation in a liquid biopsy format: LAMPing the way to an improved diagnostics and treatment // Advanced Materials Technologies. – 2025 Jul; – Vol. 10. – No. 7. – P.2401404 // doi: 10.1002/admt.202401404.
Lopez-Rios F., Angulo B., Gomez B., et al. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib // PLOS ONE. – 2013 Jan; – Vol. 8. – No. 1. – P.e53733 // doi: 10.1371/journal.pone.0053733.
Mourah S., Denis M.G., Narducci F.E., et al. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the cobas 4800 BRAF V600 Mutation Test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting // PLOS ONE. – 2015 Mar; – Vol. 10. – No. 3. – P.e0120232 // doi: 10.1371/journal.pone.0120232.
Anderson S., Bloom K.J., Vallera D.U., et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma // Archives of Pathology & Laboratory Medicine. – 2012 Nov; – Vol. 136. – No. 11. – P.1385–1391 // doi: 10.5858/arpa.2011-0505-OA.
Halait H., Demartin K., Shah S., et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma // Diagnostic Molecular Pathology. – 2012 Mar; – Vol. 21. – No. 1. – P.1–8 // doi: 10.1097/PDM.0b013e31823b216f.
Vanni I., Tanda E.T., Spagnolo F., et al. The current state of molecular testing in the BRAF-mutated melanoma landscape // Frontiers in Molecular Biosciences. – 2020 Nov; – Vol. 7. – P.113 // doi: 10.3389/fmolb.2020.00113.
Dietrich D., Uhl B., Sailer V., et al. Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition // PLOS ONE. - 2013 Oct; - Vol. 8. - No. 10. - P.e77771 // doi: 10.1371/journal.pone.0077771.
Kong H., Zhu M., Cui F., Wang S., Gao X., Lu S., et al. Quantitative assessment of short amplicons in FFPE-derived long-chain RNA // Scientific Reports. - 2014 Sep; - Vol. 4. - P.7246 // doi: 10.1038/srep07246.
Chat-Uthai N., Vejvisithsakul P., Udommethaporn S., et al. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues // PLOS ONE. - 2018 Jun; - Vol. 13. - No. 6. - P.e0198795 // doi: 10.1371/journal.pone.0198795.
Pinzani P., Salvianti F., Cascella R., et al. Allele-specific TaqMan-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients // Clinica Chimica Acta. - 2010 Nov; - Vol. 411. - No. 17-18. - P.1319–1324 // doi: 10.1016/j.cca.2010.05.024.